What is acotinib?

Acalabrutinib is an oral small molecule targeted drug that belongs to a class of drugs called BTK inhibitors. It is used primarily to treat adults with certain types of B cell lymphoma, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Bcell lymphoma is a type of leukemia or lymphoma that starts in the body's Blymphocytes. These diseases often result in abnormal cell proliferation and immune system dysfunction. BTK is a key enzyme that plays an important role in the development and function of B cells. By inhibiting the activity of BTK, acotinib interferes with the growth and proliferation of abnormal B cells and helps control the progression of the disease.

The use of acotinib is often an option considered when other treatment options, such as chemotherapy or immunotherapy, have failed or are not suitable. It has been shown to be more effective in treating CLL and SLL in some clinical trials, and is safe and tolerable compared to other drugs.

Common side effects of this drug include headache, high blood pressure, digestive problems such as vomiting and diarrhea, infections, anemia, fatigue, and more. In addition, acotinib may interact with other medications, so you should consult your doctor before use for the best treatment options.

In general, acotinib, as a targeted therapy, provides an effective treatment option for patients with Bcell lymphoma, especially for those patients who are insensitive or intolerant to traditional treatment options. It may become one of the key drugs to improve quality of life and prolong survival.